Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease

Background We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or adenocarcinoma in situ (AIS) is associated with a short interval between menarche and first sexual intercourse (FSI).Methods A total of 1009 Colombian and 1012 Finnish females, aged 16-23, who were enrolled in the phase 3 trials of a quadrivalent human papillomavirus (HPV) 6/11/16/18 vaccine had nonmissing data for age of menarche and FSI. The impact of menarche interval on the odds of developing CIN2-3/AIS was evaluated in placebo recipients who were DNA negative to HPV 6/11/16/18/31/33/35/39/45/51/52/56/58/59 and seronegative to HPV 6/11/16/18 at day 1, and had a normal Pap result at day 1 and month 7, thus approximating sexually naive adolescents (n = 504).Results The mean age of menarche and FSI was 12.4 and 16.0 years, respectively. Among the women approximating sexually naive adolescents, 18 developed CIN2-3/AIS. Compared with women who postponed FSI beyond 3 years of menarche, those with FSI within 3 years of menarche had a greater risk of cytologic abnormalities (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.02-2.68; P =. 04) and CIN2-3/AIS (OR, 3.56; 95% CI, 1.02-12.47; P =. 05).Conclusions A short interval between menarche and FSI was a risk factor for cytologic abnormalities and high-grade cervical disease. These data emphasize the importance of primary prevention through education and vaccination.Clinical Trials Registration. NCT00092521 and NCT00092534. © 2012 The Author.

• Fecha de publicación: 2012
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/22376
• Acceso en línea: https://doi.org/10.1093/infdis/jis612; https://repository.urosario.edu.co/handle/10336/22376
• Palabra clave: Oral contraceptive agent; Placebo; Virus dna; Wart virus vaccine; Adolescent; Adult; Article; Cancer risk; Colombian; Colposcopy; Condom; Confidence interval; Ethnic group; Female; Finnish; Human; Human papillomavirus type 11; Human papillomavirus type 16; Human papillomavirus type 18; Human papillomavirus type 31; Human papillomavirus type 33; Human papillomavirus type 35; Human papillomavirus type 39; Human papillomavirus type 45; Human papillomavirus type 51; Human papillomavirus type 52; Human papillomavirus type 56; Human papillomavirus type 58; Human papillomavirus type 59; Human papillomavirus type 6; Major clinical study; Menarche; Papanicolaou test; Phase 3 clinical trial (topic); Polymerase chain reaction; Post hoc analysis; Priority journal; Randomized controlled trial (topic); Risk assessment; Sexual behavior; Sexual intercourse; Uterine cervix biopsy; Uterine cervix carcinoma in situ; Uterine cervix cytology; Wart virus; Adenocarcinoma; Adolescent; Adult; Cervical intraepithelial neoplasia; Coitus; Colombia; Female; Finland; Humans; Menarche; Papillomavirus infections; Risk assessment; Sexual behavior; Time factors; Uterine cervical neoplasms; Young adult; phase iii as topic; Clinical trials
• License: Abierto (Texto Completo)